Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACER study of galantamine effects on gait variability and stability in Alzheimer's disease
2011-006011-62Phase 4Active
- Sponsor
- Slotervaartziekenhuis
- Start
- Jan 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of galantamine in Alzheimer's disease (AD) (2 arms), sponsored by Slotervaartziekenhuis. Primary endpoints: Walking variability and stability, Functional mobility and 2 more. Started Jan 2012; status: active.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2011-006011-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006011-62.